NO20041338L - Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom. - Google Patents

Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom.

Info

Publication number
NO20041338L
NO20041338L NO20041338A NO20041338A NO20041338L NO 20041338 L NO20041338 L NO 20041338L NO 20041338 A NO20041338 A NO 20041338A NO 20041338 A NO20041338 A NO 20041338A NO 20041338 L NO20041338 L NO 20041338L
Authority
NO
Norway
Prior art keywords
adults
procedure
receptor antagonist
glucocorticoid receptor
cognitive impairment
Prior art date
Application number
NO20041338A
Other languages
English (en)
Other versions
NO332723B1 (no
NO20041338D0 (no
Inventor
Joseph K Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of NO20041338D0 publication Critical patent/NO20041338D0/no
Publication of NO20041338L publication Critical patent/NO20041338L/no
Publication of NO332723B1 publication Critical patent/NO332723B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Toilet Supplies (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Casting Support Devices, Ladles, And Melt Control Thereby (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20041338A 2001-08-31 2004-03-31 Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom NO332723B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31665301P 2001-08-31 2001-08-31
PCT/US2002/027576 WO2003020216A1 (en) 2001-08-31 2002-08-27 Methods for inhibiting cognitive deterioration in adults with down's syndrome

Publications (3)

Publication Number Publication Date
NO20041338D0 NO20041338D0 (no) 2004-03-31
NO20041338L true NO20041338L (no) 2004-05-28
NO332723B1 NO332723B1 (no) 2012-12-27

Family

ID=23230024

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041338A NO332723B1 (no) 2001-08-31 2004-03-31 Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom

Country Status (15)

Country Link
US (1) US7402578B2 (no)
EP (1) EP1432379B1 (no)
JP (2) JP2005501882A (no)
KR (1) KR20040029116A (no)
CN (2) CN1868480A (no)
AT (1) ATE411013T1 (no)
CA (1) CA2459033C (no)
DE (1) DE60229411D1 (no)
ES (1) ES2314103T3 (no)
IL (1) IL160649A0 (no)
MX (1) MXPA04001893A (no)
NO (1) NO332723B1 (no)
NZ (1) NZ531477A (no)
WO (1) WO2003020216A1 (no)
ZA (1) ZA200401754B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100531738C (zh) * 2001-10-26 2009-08-26 欧加农股份有限公司 (11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
US20110166115A1 (en) * 2008-07-01 2011-07-07 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9457141B2 (en) 2013-06-03 2016-10-04 Bigfoot Biomedical, Inc. Infusion pump system and method
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
EP4157276A4 (en) 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
USD1136464S1 (en) * 2025-01-15 2026-07-21 Seth Green Coin sorter

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9807980A (pt) * 1997-02-05 2000-03-28 Allelix Pharm Eco L P Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
CA2328411C (en) * 1998-05-15 2008-12-16 Alan F. Schatzberg Glucocorticoid receptor antagonists for the treatment of dementia
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
AU2001286930A1 (en) * 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CN1547473A (zh) * 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法

Also Published As

Publication number Publication date
MXPA04001893A (es) 2005-03-07
ES2314103T3 (es) 2009-03-16
WO2003020216A1 (en) 2003-03-13
ZA200401754B (en) 2005-05-25
CN1556708A (zh) 2004-12-22
NZ531477A (en) 2006-10-27
KR20040029116A (ko) 2004-04-03
EP1432379A1 (en) 2004-06-30
US20030064974A1 (en) 2003-04-03
ATE411013T1 (de) 2008-10-15
NO332723B1 (no) 2012-12-27
DE60229411D1 (de) 2008-11-27
CN1868480A (zh) 2006-11-29
EP1432379B1 (en) 2008-10-15
JP2005501882A (ja) 2005-01-20
EP1432379A4 (en) 2005-07-13
HK1062533A1 (en) 2004-11-12
NO20041338D0 (no) 2004-03-31
CA2459033A1 (en) 2003-03-13
IL160649A0 (en) 2004-07-25
CA2459033C (en) 2012-05-22
US7402578B2 (en) 2008-07-22
JP2009102343A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
NO20041338D0 (no) Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom.
DE60228579D1 (de) Ge von antipsychotika
CA2328411A1 (en) Glucocorticoid receptor antagonists for the treatment of dementia
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NO20003534D0 (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
TR200301613T2 (tr) Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
PE34998A1 (es) Un atomizador nasal que contiene un esteroide intranasal y un antihistaminico
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
DK1267847T3 (da) 5HT2-antagonist til regulering af IOP og behandling af glaucom
ATE342721T1 (de) Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome
NO20034916D0 (no) Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av delirium
NO20023841D0 (no) Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
IL149357A0 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
NO20040104L (no) Farmasøytisk sammensetning for administrasjon ved den nasale ruten av østradiol og noretisteron
EP1726307A3 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees